Literature DB >> 36176381

Phrase of attentiveness: Use of smart phone applications for mental health concerns.

Hareem Arshad1, Samiullah Dahri2, Muhammad Yusuf Hafiz3.   

Abstract

Entities:  

Year:  2022        PMID: 36176381      PMCID: PMC9509529          DOI: 10.1016/j.amsu.2022.104783

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


× No keyword cloud information.
Mam/Sir, In the aftermath of the COVID-19 pandemic, there is an immense increment in the use of smartphone applications to assess, diagnose and treat mental health issues. Isolation and segregation due to the global pandemic that led to confinement inside homes, severe mental health concerns came into attention, and there is an enormous supplementation in the conversations around the topic globally, with the lack of provision of facilities more pronounced in an underdeveloped world in comparison to developing countries. Stigmatized mental illnesses have started to be given due importance, which has increased the demand for mental health therapists who can deal with uprising ailments. This supply demand mismatch has given birth to digital psychiatry in the form of digital smartphone applications that can be used by anyone across the globe and can connect people regardless of borders, race; color; religion; or creed. It's a provision of mental health at the doorstep without caring much about mobility for the assessment, diagnosis, monitoring, and treatment. This is indeed a good move in decreasing the prevalence of mental health concerns and further favors the issue's importance. Studies that are being conducted in this regard yield no difference in results between in-person therapy and the use of innovative smartphone applications [[1], [2], [3], [4]]. But there are a lot of limitations to the results, including reliance on patient feedback for estimation of outcomes which are themselves kept unblinded during the study period; lack of scientific investigation of rationality and validity of the results these mobile applications calculate along with the usage of assessment scales for diagnosis monitoring and follow up. It further provokes confusion about the authenticity of the results of studies that have already been done in this regard and shows no difference. So proper research should be conducted in this regard in the same way the drug trials are conducted before any new drug is approved to be utilized and made available to the general population. We further recommend welcoming an uprising of digital psychiatry but with caution; check and balance along with proper attentiveness to the fact that it doesn't become a slippery slope that leads to medical errors and loss of belief in the mental health care system worldwide that already is in the naive stages of gaining strength due to worldwide stigmatization of mental health concerns.
  4 in total

1.  A mobile app for social anxiety disorder: A three-arm randomized controlled trial comparing mobile and PC-based guided self-help interventions.

Authors:  Timo Stolz; Ava Schulz; Tobias Krieger; Alessia Vincent; Antoine Urech; Christian Moser; Stefan Westermann; Thomas Berger
Journal:  J Consult Clin Psychol       Date:  2018-06

2.  Reducing the rate of psychiatric re-admissions in bipolar disorder using smartphones-The RADMIS trial.

Authors:  Maria Faurholt-Jepsen; Morten Lindbjerg Tønning; Mads Fros; Klaus Martiny; Nanna Tuxen; Nicole Rosenberg; Jonas Busk; Ole Winther; Daniel Thaysen-Petersen; Kate Andreasson Aamund; Lizzie Tolderlund; Jakob Eyvind Bardram; Lars Vedel Kessing
Journal:  Acta Psychiatr Scand       Date:  2021-01-26       Impact factor: 6.392

3.  A telemedicine platform to improve clinical parameters in paranoid schizophrenia patients: Results of a one-year randomized study.

Authors:  Marek Krzystanek; Mariusz Borkowski; Katarzyna Skałacka; Krzysztof Krysta
Journal:  Schizophr Res       Date:  2018-08-25       Impact factor: 4.939

Review 4.  Process and Outcome Evaluations of Smartphone Apps for Bipolar Disorder: Scoping Review.

Authors:  Iona Tatham; Ellisiv Clarke; Kelly Ann Grieve; Pulkit Kaushal; Jan Smeddinck; Evelyn Barron Millar; Aditya Narain Sharma
Journal:  J Med Internet Res       Date:  2022-03-23       Impact factor: 5.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.